PrairieView Partners’s AstraZeneca AZN Stock Holding History

PrairieView Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-46	Closed	-$6K	–	362
2023 Q3	$6K	Hold	46	–	–	﹤0.01%	306
2023 Q2	$6K	Hold	46	–	–	﹤0.01%	351
2023 Q1	$6K	Hold	46	–	–	﹤0.01%	335
2022 Q4	$6K	Sell	46 -35	-43%	-$4.39K	﹤0.01%	347
2022 Q3	$9K	Buy	+81	New	+$10.3K	﹤0.01%	308
2022 Q1	–	Sell	-932	Closed	-$109K	–	442
2021 Q4	$109K	Buy	+932	New	+$110K	0.02%	149

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

PrairieView Partners's AZN Position: Q4 2023 in Review

PrairieView Partners sold out of AstraZeneca (AZN) in Q4 2023, closing a stake of 46 shares — an estimated $6K sold.

PrairieView Partners first reported a position in AZN in Q4 2021 and held it in 6 quarters. The position peaked at $109K in Q4 2021. 1,130 funds tracked by Wall St. Rank hold AZN as of Q4 2023.

PrairieView Partners reported no remaining AstraZeneca position as of Q4 2023 after selling out during the quarter.
PrairieView Partners sold 46 AstraZeneca shares in Q4 2023, an estimated $6K.
PrairieView Partners first reported a position in AstraZeneca in Q4 2021 and held it in 6 quarters.
PrairieView Partners's AstraZeneca position peaked at $109K in Q4 2021.
1,130 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2023.

Based on PrairieView Partners's 13F filing for Q4 2023, filed 26 Jan 2024.